Top

Published in:

01-09-2018 | Commentary

Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab

Authors: Carlo Putzu, Diego Luigi Cortinovis, Francesca Colonese, Stefania Canova, Ciriaco Carru, Angelo Zinellu, Panagiotis Paliogiannis

Published in: Cancer Immunology, Immunotherapy | Issue 9/2018

Abstract

Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer. Nivolumab, a monoclonal antibody that targets programmed death-1 (PD-1), was the first immune checkpoint inhibitor approved for the treatment of patients with advanced/metastatic NSCLC not responding to platinum-based chemotherapy. Biomarkers predicting response to these therapies would allow early identification of non-responders and timely implementation of appropriate combination strategies, avoiding inadequate and expensive therapies. The role of the neutrophil to lymphocyte ratio and other blood cell count indexes as possible biomarkers of response has been recently investigated. We discuss the encouraging results reported on the topic, provide new data from our personal experience, and discuss opportunities for further research.

Paliogiannis P, Attene F, Cossu A, Budroni M, Cesaraccio R, Tanda F, Trignano M, Palmieri G (2013) Lung cancer epidemiology in North Sardinia, Italy. Multidiscip Respir Med 8:45. https://doi.org/10.1186/2049-6958-8-45 CrossRefPubMedPubMedCentral

Paliogiannis P, Attene F, Cossu A et al (2015) Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Mol Med Rep 12:187–191. https://doi.org/10.3892/mmr.2015.3347 CrossRefPubMedPubMedCentral

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Cortinovis DL, Canova S, Abbate M, Colonese F, Bidoli P (2016) Focus on nivolumab in NSCLC. Front Med (Lausanne) 3:67. https://doi.org/10.3389/fmed.2016.00067 PubMedCentralCrossRef

Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924–3933. https://doi.org/10.1200/JCO.2017.74.3062 CrossRefPubMedPubMedCentral

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M (2017) Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2017.12.007 CrossRefPubMed

Yao C, Liu X, Tang Z (2017) Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis 12:2285–2290. https://doi.org/10.2147/COPD.S141760 CrossRefPubMedPubMedCentral

Yang Z, Zhang Z, Lin F, Ren Y, Liu D, Zhong R, Liang Y (2017) Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS 125:863–871. https://doi.org/10.1111/apm.12722 CrossRefPubMed

Paliogiannis P, Scognamillo F, Bellomo M, Pittalis ML, Pisano IP, Karligkiotis A, Bozzo C, Sotgiu G, Attene F (2015) Neutrophil to lymphocyte ratio as a predictor of thyroid papillary carcinoma. Acta Med Mediterr 31:371–375

10.

Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134:2403–2413. https://doi.org/10.1002/ijc.28536 CrossRefPubMed

11.

Kara M, Uysal S, Altinişik U, Cevizci S, Güçlü O, Dereköy FS (2017) The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol 274:535–542. https://doi.org/10.1007/s00405-016-4250-8 CrossRefPubMed

12.

Wang L, Liang D, Xu X, Jin J, Li S, Tian G, Gao Z, Liu C, He Y (2017) The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. Oncol Lett 14:6449–6456. https://doi.org/10.3892/ol.2017.7047 PubMedPubMedCentralCrossRef

13.

Yu Y, Qian L, Cui J (2017) Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol 7:498–506. https://doi.org/10.3892/mco.2017.1342 CrossRefPubMedPubMedCentral

14.

Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013 CrossRefPubMed

15.

Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357. https://doi.org/10.1001/jamaoncol.2017.4771 CrossRefPubMed

16.

Shiroyama T, Suzuki H, Tamiya M et al (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7:13–20. https://doi.org/10.1002/cam4.1234 CrossRefPubMed

17.

Kiriu T, Yamamoto M, Nagano T et al (2018) The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One 13:e0193018. https://doi.org/10.1371/journal.pone.0193018 CrossRefPubMedPubMedCentral

18.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS (2017) Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 67:459–470. https://doi.org/10.1007/s00262-017-2092-x CrossRefPubMed

Title: Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
Authors: Carlo Putzu
Diego Luigi Cortinovis
Francesca Colonese
Stefania Canova
Ciriaco Carru
Angelo Zinellu
Panagiotis Paliogiannis
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 9/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2182-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2018

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells

Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells

“Pseudoprogression”: more than semantics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer